Business Context and Reporting Period
Company: DAXOR CORP
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2006
Business Overview: Daxor is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and related diagnostic kits (Volumex). It also operates a cryobanking subsidiary (Scientific Medical Systems Corp.) for blood and semen storage. A significant portion of the company's financial stability relies on a large investment portfolio of utility stocks and derivatives, which offsets operating losses.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 |
Six Months Ended June 30, 2006 |
|---|---|---|
| Revenues | $389,322 | $731,468 |
| Gross Profit | $180,321 | $403,594 |
| Operating Loss | $(1,525,606) | $(2,797,725) |
| Investment Income (Net) | $1,746,073 | $3,073,523 |
| Net Income (Loss) | $134,320 | $95,338 |
| Cash and Equivalents | $28,646 | $28,646 |
| Available-for-Sale Securities | $59,260,152 | $59,260,152 |
| Total Assets | $61,307,973 | $61,307,973 |
| Total Liabilities | $20,605,642 | $20,605,642 |
| Stockholders' Equity | $40,702,331 | $40,702,331 |
| Loans Payable (Current) | $5,619,317 | $5,619,317 |
Note: Net income is primarily driven by investment gains rather than core operations. Operating cash flow for the six months ended June 30, 2006, was negative $(2,263,036).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenues increased 35.3% for the quarter and 24.3% for the six months compared to the prior year. This was driven by a 40.2% increase in Volumex kit sales and the sale of one BVA-100 unit, attributed to the correction of a Medicare reimbursement error in early 2006.
- Cryobanking Decline: Cryobanking revenues decreased 16.4% for the quarter and 7.2% for the six months, due to reductions in semen storage and analysis services.
- Investment Performance: Investment income surged to $1.75 million for the quarter (vs. a loss of $8,727 in 2005) and $3.07 million for the six months (vs. $797,314 in 2005). This improvement was largely due to a $509,092 gain from marking short positions to market, compared to an $882,719 loss in the prior year.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 31.4% for the quarter, driven by expanded R&D and marketing efforts for the BVA-100.
- Restatements: Prior year (2005) financial data was restated to correct accounting errors regarding the valuation of options/short sales, capitalization of equipment, and revenue recognition methods.
Guidance, Outlook, and Risks
- Outlook: Management anticipates increased acceptance of blood volume measurement following the Medicare reimbursement correction. The company is negotiating "Blood Optimization Programs" with hospitals to install BVA-100 units and utilize cryobanking services.
- R&D Focus: Continued investment in R&D for Glomerular Filtration Rate (GFR) testing, Total Body Albumin Analysis, and a needle-free delivery device (Max-200).
- Liquidity: The company maintains a large investment portfolio (approx. $59.3 million) to offset operating losses. However, cash and cash equivalents are low ($28,646), and the company relies on margin loans ($5.6 million) secured by these securities.
- Internal Controls: Management disclosed that internal controls over financial reporting were deemed ineffective as of June 30, 2006, due to insufficient personnel with GAAP expertise. A CPA was hired in late 2005 to oversee improvements, but the system is still undergoing changes.
- Market Risk: The portfolio is heavily concentrated in electric utility stocks. Risks include interest rate fluctuations affecting stock valuations and the potential for preferred stocks to be called away, reducing dividend yields.
Investor Verification Checklist
- Operating Viability: Verify if the core medical device business can achieve profitability without reliance on investment income, given the persistent operating losses.
- Investment Concentration: Assess the risk of the portfolio being 80%+ in electric utilities and the impact of interest rate hikes on asset valuation.
- Internal Controls: Monitor the progress of internal control remediation to ensure future financial reporting accuracy, given the recent restatements.
- Liquidity Position: Review the sustainability of the margin loan structure ($5.6M debt) against the low cash balance ($28k) and the potential need to liquidate securities to meet obligations.
- Medicare Reimbursement: Confirm the stability of the corrected Medicare reimbursement rates for Volumex kits, which drove recent revenue growth.